Fingolimod (Gilenya) not effective in primary progressive MS
Author: MS Trust
Fingolimod (Gilenya) was no better than placebo at reducing measures of progression in people with primary progressive MS according to information announced today.
The INFORMS trial was the largest study so far in primary progressive MS. 970 people in 18 countries were treated with fingolimod or placebo for three years and different aspects of disability were regularly measured. A press release from Novartis, who manufacture fingolimod and ran the trials, says that there was no difference in the risk of progression between the treatment and placebo groups. More detailed results of the study will be presented at a scientific conference.
Fingolimod is already available as a treatment for people with relapsing remitting MS. INFORMS was prompted by evidence that suggested that the way the drug works might also benefit people with progressive MS.
There has been an increasing focus of research on progressive forms of MS in recent years. In 2012 an international group of MS organisations and researchers set up the Progressive MS Alliance encourage and promote research. Studies are now underway following the awarding of the first grants in the summer.
Amy Bowen, the MS Trust's Director of Service Development said,
"It is disappointing that the INFORMS trial has not produced a positive result. Finding a treatment that is going to change the course of progressive MS is a huge challenge. The MS Trust supports the work of the Progressive MS Alliance and the international commitment to find new treatments for progressive MS."
Although there are currently no disease modifying drugs for people with progressive MS, there is support for managing symptoms and with rehabilitation approaches.
Amy Bowen added,
"People living with MS of all types need access to support and specialist care right now and the MS Trust is committed to ensuring that there are enough trained specialist nurses, physiotherapists, occupational therapists and neurologists across the UK so that everyone with MS gets the high quality expert care they need."
Find out more


Updated NICE multiple sclerosis guideline contains some good news and some bad news
22/06/2022 - 00:00
There are some positive points in the revised 2022 guideline but the MS Trust is disappointed that NICE has been unable to recommend Fampyra.


Connors letter to MS
21/06/2022 - 00:00
In 2022, Connor will be taking part in the Great North Run to support the MS Trust. Here, Connor writes a letter to MS, openly sharing his thoughts on the condition his sister was diagnosed with at the age of 14.


Why is Pride month important to the MS Trust?
16/06/2022 - 00:00
As part of our Pride month celebrations, two of the MS Trust team who identify as members of the LGBTQ+ community, sat down with David Martin, the MS Trust’s CEO, to discuss the importance of celebrating the LGBTQ+ community - not just in June but throughout the year.

Sign up for updates from us
Keep up-to-date with the latest MS news, explore new research, read the stories of people living with MS, find out practical tips from MS experts, and discover exciting fundraising opportunities.